Prot #101MS329: A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching Fro

Project: Research project

Project Details

StatusFinished
Effective start/end date6/14/19 → 12/1/22

Funding

  • Quintiles, Inc. (Prot #101MS329 // Prot #101MS329)
  • Biogen MA Inc. (Prot #101MS329 // Prot #101MS329)